Originally reported to inhibit PFKFB3 (IC50 = 25 μM). More recent reports failed to demonstrate activity in a PFKFB3 kinase assay. Reduces glycolytic flux and suppresses glucose uptake. Inhibits endothelial cell proliferation and causes G2/M cell cycle arrest in vitro. Attenuates vessel sprouting and tumor growth in vivo. Amplifies the antiangiogenic effect of VEGFR blockade. Purity 99%. MW (observed): 210.23